Type

Range

Units

Status

Start Date

End Date

Financing

Study Design

Keywords

Homepage

Brief description/objective

Breast cancer is the most frequent malignancy in women and the
leading cause of cancer mortality in most countries in Europe.
Metastatic breast cancer remains an incurable disease with a
median overall survival (OS) of 2–4 years and a 5 year survival
of only 25%. Patients with hormone receptor (HR)-positive breast cancer involving visceral disease at diagnosis have an even worse
outcome.
Many oncologists still prefer to treat visceral diseases primarily with chemotherapy rather than with endocrine
treatment, thinking to receive a faster response with chemothera-py than with endocrine therapy, especially in patients with clinical
symptoms or potentially threatening lesions. However,
results from cross-sectional clinical practice studies suggest
that endocrine therapy is associated with better quality of life,
fewer concerns about side effects, less activity impairment and
higher treatment satisfaction compared to chemotherapy. In addition,
with the new data of CDK4/6 inhibitors combined with endocrine
treatment we now have even better efficacy data compared to
endocrine therapy alone.